Highly Selective Y₄ Receptor Antagonist Binds in an Allosteric Binding Pocket.

Area of Science:

• Pharmacology
• Neuroscience
• Biochemistry

Background:

• Human neuropeptide Y receptors (Y1R, Y2R, Y4R, Y5R) are G protein-coupled receptors crucial for regulating food intake and energy metabolism.
• Targeting these receptors offers potential therapeutic strategies for metabolic diseases.

Purpose of the Study:

• To identify and characterize the first selective Y4R allosteric antagonist.
• To elucidate the antagonistic mechanism of the novel compound (S)-VU0637120.
• To validate Y receptors as therapeutic targets for metabolic disorders.

Main Methods:

• In vitro, ex vivo, and in silico studies were employed.
• Characterization of the selective Y4R allosteric antagonist (S)-VU0637120.
• Analysis of the binding site and inhibitory mechanism.

Main Results:

• The first selective Y4R allosteric antagonist, (S)-VU0637120, was identified and characterized.
• (S)-VU0637120 selectively inhibits native Y4R function.
• The compound binds to an allosteric site within the Y4R transmembrane domains, distinct from the endogenous ligand binding pocket.

Conclusions:

• The development of (S)-VU0637120 provides a novel tool for studying Y4R function.
• This research advances the understanding of allosteric modulation in peptide-activated G protein-coupled receptors (GPCRs).
• Findings contribute to the rational design of allosteric modulators for treating metabolic diseases.